Shionogi
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Shionogi sits in the top decile of US sponsors by registered trial count (#351 of 15,742 sponsors by registered trial count).
Shionogi: 54 sponsored US clinical trials, 5 recruiting.
Shionogi sponsors 54 registered US clinical trials on ClinicalTrials.gov, 5 of them currently recruiting, and 43 completed. 10 of these trials are in Phase 3-4 (later-stage) and 42 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy Volunteers, with 3 trials.
Top-decile sponsor footprint
Shionogi ranks in the top decile of sponsors by registered trial count (#351 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
43 of 47 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
54 total, page 1 of 2
A Study of S-337395 in Symptomatic Nonhospitalized Adults With Respiratory Syncytial Virus (RSV) Who Are at High Risk of Progression to Severe Disease
NCT07214571
Study of S-606001 as an Add-on to Enzyme Replacement Therapy (ERT) in Participants With Late-onset Pompe Disease (LOPD)
NCT07123155
A Study of S-892216-PO in Participants With Renal Impairment and Matched Controls
NCT07217886
Study of S-892216 Long-acting Injectable (LAI) in Healthy Adult Participants
NCT07093580
S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors
NCT05101070
Study of Zatolmilast (BPN14770) in Participants With PPP2R5D Neurodevelopmental Disorder (Jordan's Syndrome [JS])
NCT06717438
A Phase 2b, Randomized, Double-blind Study of Redasemtide (S-005151) in Adult Participants With Acute Ischemic Stroke
NCT05953480
Phase 1 Study of BPN14770 in Participants With Hepatic Impairment and Healthy Controls
NCT07018492
Study of BPN14770 in Participants With Severe Renal Impairment and Healthy Controls
NCT07012005
A Study to Assess the Effects of BPN14770 on Rosuvastatin
NCT07011992
A Study of S-892216 in Participants With COVID-19
NCT06928051
A Drug-Drug Interaction Study of S-217622 With Combined Oral Contraceptives in Healthy Adult Female Participants
NCT06775730
A Drug-drug Interaction Study of S-892216 Coadministered With Carbamazepime to Healthy Adult Participants
NCT06751017
A Study to Investigate How Respiratory Syncytial Virus (RSV) Infection Develops and Changes Over Time in Pediatric Participants
NCT06746051
A Study of S-740792 in Healthy Adult Study Participants
NCT06724978
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Cefiderocol in Hospitalized Neonates and Infants
NCT06086626
A Study to Investigate Different Formulations of S-337395 in Healthy Adult Participants
NCT06270511
Effect of Administration of Itraconazole on the Pharmacokinetics of S-309309 in Healthy Participants
NCT06106334
Safety and Efficacy Study of S-309309 in Obese Adults
NCT05925114
Phase 3 Study of S-217622 in Prevention of Symptomatic SARS-CoV-2 Infection
NCT05897541
A Study to Assess S-217622 in Participants With Mild and Moderate Hepatic Impairment and Healthy Control Participants
NCT05409911
A Study to Assess S-217622 in Participants With Renal Impairment and Healthy Participants
NCT05363215
A Study to Compare S-217622 With Placebo in Non-Hospitalized Participants With COVID-19
NCT05305547
A Study to Assess the Effect of Cefiderocol on the Pharmacokinetics (PK) of Midazolam in Healthy Participants
NCT05395104
A Study to Assess S-309309 in Healthy and Obese Participants
NCT05247970
A Study of Naldemedine in Participants Undergoing Surgeries That Include a Bowel Resection or Bowel Transection
NCT04355169
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Cefiderocol in Hospitalized Pediatric Participants
NCT04215991
Evaluation of S-600918 in Adults With Refractory Chronic Cough
NCT04110054
Radicava® (Edaravone) Findings in Biomarkers From ALS (REFINE-ALS)
NCT04259255
Evaluation of Safety, Tolerability, Pharmacokinetics, Drug-Drug and Food Interactions of Single and Multiple Doses of S-648414 in Healthy Adults
NCT04147715
Cefiderocol Concentrations in the Lungs of Hospitalized Patients With Bacterial Pneumonia
NCT03862040
Clinical Study of Cefiderocol (S-649266) for the Treatment of Nosocomial Pneumonia Caused by Gram-negative Pathogens
NCT03032380
Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens
NCT02714595
Efficacy and Safety of Naldemedine in Treating Opioid-induced Constipation
NCT01993940
Long Term Safety of Naldemedine
NCT01965652
Efficacy and Safety of Naldemedine in the Treatment of Opioid-induced Constipation
NCT01965158
A Study of Naldemedine (S-297995) for the Treatment of Opioid-Induced Constipation in Adults With Non-Malignant Chronic Pain Receiving Opioid Therapy
NCT01443403
Safety and Efficacy of S-707106 in Subjects With Type 2 Diabetes Mellitus and Inadequate Glycemic Control With Metformin Therapy
NCT01240759
Study to Assess Safety and Pharmacokinetics of Double-Blind S-707106 Alone and in Combination With Open-Label Metformin in Patients With Type 2 Diabetes Mellitus
NCT01154348
Study to Evaluate the Safety and Efficacy of Naldemedine (S-297995) for the Treatment of Opioid-Induced Bowel Dysfunction in Subjects With Chronic Pain
NCT01122030
An Open-label Safety Study of Lusutrombopag (S-888711) in Adults With Chronic Immune Thrombocytopenia (ITP)
NCT01129024
Double-Blind, Multi-Center, Randomized Study to Assess the Efficacy and Safety of Velneperit (S-2367) and Orlistat Administered Individually or Combined With a Reduced Calorie Diet (RCD) in Obese Subjects
NCT01126970
A Study to Investigate the Efficacy and Safety of Lusutrombopag (S-888711) Tablets Administered to Adults With Immune Thrombocytopenia (ITP)
NCT01054443
Effect of Food and Calcium on Pharmacokinetics of a Single Dose of S-888711 in Healthy Adult Volunteers
NCT03897413
Open-Label Extension (OLE) Study for Safety and Efficacy of Velneperit (S-2367) in Obese Subjects
NCT00788528
A Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of 2 Doses of S-777469 in Patients With Atopic Dermatitis
NCT00703573
Open-Label, Chronic Exposure, Safety Study of CLONICEL (Clonidine HCl Sustained Release) in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)
NCT00723190
A Phase Ib/IIa, Double-Blind, Randomized Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of S-777469 in Subjects With Atopic Dermatitis
NCT00697710
Phase IIb One Year Efficacy and Safety Study of S-2367 in Obese Subjects With Initial 6-Week Low Calorie Diet
NCT00748605
Phase IIb One Year Efficacy and Safety Study of S-2367 in Obese Subjects With Reduced Calorie Diet
NCT00747929
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 22 |
| Phase 2 | 20 |
| Phase 3 | 10 |
Therapeutic Areas
What is open in the Shionogi pipeline
5 recruiting of 54 indexed (9% open); 43 completed (80%).
Phase mix: 10 late (III/IV) vs 42 early (I/II) (early-phase heavy).
Top condition: Healthy Volunteers (3 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Shionogi: open-pipeline peers nationwide
Peers matched on 54 registered trials and 9% open enrollment, not the therapeutic-area sidebar.
Shionogi sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 54 trials (± recruiting share)
- AdventHealth Translational Research Institute · 54 trials · 24% recruiting
- Auburn University · 54 trials · 24% recruiting
- Brooke Army Medical Center · 54 trials · 11% recruiting
- Corcept Therapeutics · 54 trials · 11% recruiting
Sponsors near 9% open enrollment (± trial volume)
- University of Kentucky · 9% recruiting · 54 trials
- University of Vermont · 9% recruiting · 162 trials
- Eli Lilly and Company · 9% recruiting · 1,341 trials
- Lahey Clinic · 9% recruiting · 43 trials
Related
What to do with this Shionogi page
54 registered trials is a research-attention snapshot, not an endorsement of Shionogi or any single study.
- 5 of Shionogi's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Healthy Volunteers is the condition Shionogi studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Healthy Volunteers trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Shionogi pipeline card: 54 registered trials from official public datasets.Report a data error.